News

Panel of TB experts releases report calling for the prioritization of tuberculosis R&D

On June 9th, the Center for Strategic and International Studies (CSIS) released six policy reports detailing the domestic and global health burden of tuberculosis and recommendations for the United States government to combat the disease. The policy reports were the culmination of major findings from the CSIS Global Health Policy Center (GHPC), a working group composed of leading tuberculosis experts. In summary, the GHPC overview report titled “Strengthening the U.S. Approach to Tuberculosis Research and Development” called for the prioritization of TB R&D by the provision of more resources for research and innovation. To read the overview report click here. The six major reports released by the CSIS Global Health Policy Center can be found here.

Related Links

A Strategic Approach to Global Tuberculosis

Tuberculosis R&D must be U.S. diplomatic priority, say global health leaders

Tuberculosis panel: U.S. effort must focus, prioritize, coordinate

Additional Links

Center for Strategic and International Studies

CSIS Global Health Policy Center

More News
14 Aug 2019
FDA released the following press release on Wednesday, August 14th: The U.S. Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis (TB) of the lungs. “The threat of...
27 Jun 2019
-- Globe Newswire reported on June 20th -- Spero Therapeutics, Inc. , a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today...
5 Jun 2019
**Update: The US FDA Antimicrobial Drug Advisory Committee voted in favor of the NDA 14 to 4 on June 6th, 2019** The United States Food & Drug Administration (FDA) will host the Antimicrobial Drug Advisory Committee on Thursday, June 6th to discuss the new drug application (NDA) involving new...